{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004085","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.396929+00:00","generated_at":"2026-06-19T02:32:16.618824+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Personalis reports Q4 2022 revenue $16.7M, net loss $31.1M; guides FY2023 revenue $68-72M","bullets":["Q4 2022 revenue $16.7M, full year $65.0M; net loss Q4 $31.1M ($0.67/share), full year $113.3M ($2.48/share).","Cash and investments $167.7M at Dec 31, 2022; FY2023 cash usage guided to ~$75M, down from $119M in 2022.","Partnership with Moderna for genomic testing in personalized cancer vaccine trials; MRD validation study with Criterium and ABRCC.","Strategic review completed; new focus on MRD, personalized cancer vaccines, and pharma clinical trial support.","FY2023 net loss guided to ~$103M, improved from $113M in 2022 due to headcount reduction savings."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004085","json":"https://secwatch.observer/filing/0000950170-23-004085.json","markdown":"https://secwatch.observer/filing/0000950170-23-004085.md","text":"https://secwatch.observer/filing/0000950170-23-004085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/0000950170-23-004085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/psnl-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:32:16.618824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c3d8634c8d707f9c4be5b07f6c5bda031615301","claim":"Personalis, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022, net income Net loss of $31.1 million, and net loss per share of $0.67 ... in the fourth quarter 2022; net loss of $113.3 million, a, EPS $0.67 ... in the fourth quarter 2022; ... $2.48 ... in the full year 2022. Guidance initiated.","evidence_excerpt":"Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/0000950170-23-004085-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022"},{"label":"Net income","value":"Net loss of $31.1 million, and net loss per share of $0.67 ... in the fourth quarter 2022; net loss of $113.3 million, a"},{"label":"EPS","value":"$0.67 ... in the fourth quarter 2022; ... $2.48 ... in the full year 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}